Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.6.4 has been added and Revision: v3.6.3 removed, indicating a minor version update to the page's release notes/metadata. This update updates the version label on the page to reflect a new release and may accompany small UI or data adjustments.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedA new publication related to the study has been added to Publications (Telisotuzumab Vedotin in c-Met+ NSCLC), and the page shows a new revision (v3.6.3) with the older version (v3.6.1) removed, indicating an updated study record.SummaryDifference0.0%

- Check31 days agoChange DetectedRevision updated from v3.6.0 to v3.6.1, representing a minor publication release of the page. No content changes are indicated by the change data.SummaryDifference0.0%

- Check45 days agoChange DetectedRecruitment is now shown as closed for this study, and new navigation links for How to Read a Study Record, Common Questions, and How to Join a Study have been added. There are also minor formatting tweaks to the Intervention/Treatment heading and to the revision notes.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision version updated from v3.5.4 to v3.5.5, reflecting a minor update to the page's revision tracking.SummaryDifference0.0%

- Check67 days agoChange DetectedExpanded access status on the study page changed from Available (v3.5.3) to Temporarily not available (v3.5.4). This reflects that expanded access is not currently available outside the trial.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.